Literature DB >> 352210

Influenza immunization in systemic lupus eruthematosus. A double-blind trial.

G W Williams, A D Steinberg, J L Reinertsen, L W Klassen, J L Decker, R Dolin.   

Abstract

Forty patients with systemic lupus erythematosus randomly received inactivated bivalent (A/NJ and A/Victoria) influenza vaccine or saline in a double-blind study. During 20 weeks of follow-up, no deterioration in major organ function or increase in disease flares was observed in the immunized group as compared with the group that received saline. Preimmunization antibody titers to A/Victoria were lower in the 40 patients with lupus erythematosus than in age-matched control subjects. Response to immunization, as measured by serum antibody titers, was also lower in the patients with lupus erythematosus, indicating that immune responses must be evaluated on an individual patient basis. Nevertheless, influenza vaccination can be safely carried out in patients with systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 352210     DOI: 10.7326/0003-4819-88-6-729

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.

Authors:  A Holvast; A Huckriede; J Wilschut; G Horst; J J C De Vries; C A Benne; C G M Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

3.  Antigen specific immune response potential and HLA typing of Israeli patients with thyroid autoimmune diseases (TAD).

Authors:  Y Shalev; Z Bentwich; D Katz; C Brautbar; E Mozes
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

Review 4.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

Review 5.  Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  L Turner-Stokes; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-07       Impact factor: 19.103

Review 6.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

7.  Properties of the ribosomal P2 protein autoantigen are similar to those of foreign protein antigens.

Authors:  K Elkon; E Bonfa; R Llovet; W Danho; H Weissbach; N Brot
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

8.  Immune response to influenza vaccine in children with inflammatory bowel disease.

Authors:  Ying Lu; Denise L Jacobson; Lori A Ashworth; Richard J Grand; Anthony L Meyer; Monica M McNeal; Matt C Gregas; Sandra K Burchett; Athos Bousvaros
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

9.  Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen.

Authors:  A B Gottlieb; R G Lahita; N Chiorazzi; H G Kunkel
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

Review 10.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.